Table 2.

Ongoing trials with PD-1 pathway-targeted immunotherapy

IndicationCompoundNCT#PhaseSponsorDescription or control armExpected patient enrollmentExpected completion date
Metastatic BRAFV600+ melanomaMPDL3280A/RG7446 with vemurafenibNCT016566421Genentech3 Arms, no dose info44November, 2014
mMELNivolumab with ipilimumabNCT010242311Bristol-Myers SquibbVarying doses of nivolumab + ipilimumab or nivolumab only64August, 2014
Resected melanomaNivolumab with vaccineNCT011764741H. Lee Moffitt Cancer CenterNivolumab dose-escalation + vaccine30July, 2013 (primary)
Unresectable melanomaNivolumab with vaccineNCT011764611H. Lee Moffitt Cancer CenterNivolumab dose-escalation + vaccine85June, 2014 (primary)
MelanomaNivolumab (biomarker identification)NCT016214901Bristol-Myers Squibb3 mg/kg, single arm80December, 2015
MelanomaCT-011NCT014353692CureTech, LTD.1.5 vs. 6 mg/kg100March, 2014
Hematologic malignanciesNivolumabNCT015923701Bristol-Myers SquibbDose-escalation110February, 2015
Multiple myeloma after SCTCT-011 with DC/MM vaccineNCT010672872Beth Israel Deaconess Med CtrCT-011 alone35March, 2013
Relapsed follicular lymphomaCT-011 with rituximabNCT009047222CureTech, LTD.3 mg/kg, single arm30June, 2013
Diffuse large B-cell lymphoma after ASCTCT-011NCT005322592CureTech, LTD.1.5 mg/kg, single arm70August, 2011 (but final data not yet reported)
Acute myelogenous leukemiaCT-011 with DC/AML vaccineNCT010966022Beth Israel Deaconess Med CtrDC/AML vaccine alone35May, 2013
RCCNivolumab (biomarker identification)NCT013587211Bristol-Myers Squibb0.3, 2, and 10 mg/kg (one group no previous treatment)80August, 2015
RCCNivolumab with sunitinib or pazopanibNCT014720811Bristol-Myers SquibbNivolumab + pazopanib vs. nivolumab + sunitinib72August, 2013
RCCCT-011 with DC/RCC vaccineNCT014417652Beth Israel Deaconess Med CtrCT-011 alone44November, 2013
RCCNivolumabNCT013544312Bristol-Myers Squibb0.3, 2, and 10 mg/kg arms150November, 2012
Advanced or mRCCNivolumabNCT016687843Bristol-Myers SquibbEverolimus822February, 2016
Multiple solid tumorsMPDL3280A/RG7446 with bevacizumabNCT016339701GenentechDose-escalation with or without chemotherapy68March, 2015
Multiple solid tumorsMK-3475NCT012958271Merck1, 3, and 10 mg/kg arms439March, 2015
Multiple solid tumorsAMP-224NCT013528841Amplimmune, GlaxoSmithKlineDose-escalation63July, 2013
Multiple solid tumorsMPDL3280A/RG7446NCT013758421GenentechDose-escalation88July, 2013
Multiple solid tumorsBMS-936559NCT007296641Bristol-Myers SquibbDose-escalation286September, 2013
Multiple solid tumorsNivolumabNCT007306391Bristol-Myers SquibbDose-escalation290October, 2015
Multiple solid tumorsNivolumabNCT008368881Ono Pharmaceutical Co.Dose-escalation24September, 2010 (primary)
Multiple solid tumorsMEDI4736NCT016935621MedImmune LLC.Dose-escalation110November, 2014
Multiple solid tumorsNivolumabNCT016297581Bristol-Myers SquibbIL-21 dose-escalation, with 3 mg/kg nivolumab160September, 2015
NSCLCNivolumab with various chemotherapiesNCT014541021Bristol-Myers SquibbNivolumab alone vs. with 1/5 chemotherapies108December, 2013
Squamous NSCLCNivolumabNCT016420043Bristol-Myers SquibbDocetaxel264August, 2014
Nonsquamous NSCLCNivolumabNCT016738673Bristol-Myers SquibbDocetaxel574November, 2014
Hepatocellular carcinoma (┬▒HCV or HBV)NivolumabNCT016588781Bristol-Myers SquibbDose-escalation; no infection vs. HCV vs. HBV72April, 2014
Pancreatic cancerCT-011 with Sipuleucel-T and cyclophosphamideNCT014209652Georgia Health Sciences UniversitySipuleucel-T vs. Sipuleucel-T plus CT-011 vs. Sipuleucel-T plus CT-011 plus cyclophosphamide57December, 2017
Pancreatic cancerCT-011 with gemcitabineNCT013134162Georgia Health Sciences UniversitySingle arm29February, 2017
Metastatic colorectal cancerCT-011 with FOLFOXNCT008903052CureTech, LTD.FOLFOX alone168September, 2012